Diovan Articles
BI's Micardis provides sustained BP control
28 June 2004
Novartis says yes to Aventis merger talks
26 April 2004
Novartis files for new use of Diovan
9 February 2004
Banyu aims for 30% Nu-lotan market share
19 January 2004
Stock Commentary - Europe
17 November 2003
Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver
27 October 2003
Novartis' Diovan cuts atrial fibrillation
8 September 2003
Swiss OK for new use of Novartis' Diovan
4 August 2003
Beaufour Ipsen to sell valsartan in France
19 May 2003
Profits flat at Novartis despite sales growth
21 April 2003
Schwarz forecasts two-fold earnings growth in 2003
3 March 2003
Novartis sales grow 12% in 2nd qtr
29 July 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Hypertension market set for major change.
21 January 2002
Val-HeFT data on Novartis' Diovan published in NEJM
7 December 2001
Schwarz Pharma looks to have turned corner
12 November 2001
Novartis' Rx discount card for US seniors
8 November 2001
Novartis sent approvable letter for Diovan in CHF
25 October 2001
Diovan approval with clean label unlikely, say analysts
22 October 2001
FDA panel split on Diovan use in CHF
12 October 2001
Double-digit turnover growth for Novartis
11 October 2001
Novartis launches largest diabetes study
13 September 2001
Novartis' six-month 2001 net income jumps 10%, sales up 11%
16 August 2001
CORRECTION: CEPA's valsartan
8 August 2001
CORRECTION: Novartis/Schwarz deal
7 August 2001
Novartis and Schwarz extend valsartan deal
23 July 2001
Novartis completes VALIANT enrolment
10 July 2001
Major study looks at Novartis drugs in IGT
26 June 2001
Novartis files sNDA with FDA for Diovan
3 May 2001
Novartis 1st qtr pharma sales rise 13%
19 April 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Novartis expanding staff in Japan
23 January 2001
Stock Commentary - Europe
23 November 2000
Novartis to file for new Diovan label, in heart failure treatment
16 November 2000
Approvable letter for Novartis' Zometa
28 September 2000
Approvable letter for Novartis' Zometa
22 September 2000
Novartis puts in solid 1st-half performance
21 August 2000
Japan advisory panel to review SB Paxil dossier
3 August 2000
Sankyo seeks FDA OK for hypertension drug
1 August 2000
New study shows similar efficacy of AIIRAs
11 May 2000
VALUE study tops enrollment target
2 March 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Schwarz Pharma profits fall 42%
16 February 2000
Novartis' Trileptal cleared in EU
9 December 1999
Novartis upbeat at biannual R&D update
23 September 1999
Solvay's Teveten, more effective than other ARBs?
3 September 1999
Schwarz licenses valsartan rights from Novartis
20 May 1999
1st-qtr 1999 sales dip for Novartis
21 April 1999
Beyond ACE inhibition: the future of angiotensin I inhibitors
11 February 1999
Novartis 1998 sales down on forecasts
21 January 1999
Telmisartan Becomes Sixth AIIRA To Be Registered
19 November 1998
"Underlying Quality" In Novartis' Growth
2 November 1998
Pharma Sales Give Novartis Boost
22 October 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Novartis First Half Sales Under Expectations
16 July 1998
UK Hypertension Market To 2007
27 May 1998
Modest Rise In Sales At Novartis Lower Than Expected
22 April 1998
Hypertension: AIIRAs Set To Boom
21 April 1998
GW Makes Foray Into Cardiovascular Arena
18 March 1998
FDA Approvals In Brief
11 March 1998
Wyeth-Ayerst's Verdia Cleared By FDA Panel
4 February 1998
1st Launches For Novartis' Exelon And CoDiovan
21 November 1997
Diovan Versus Norvasc Trial
9 October 1997
First Market For Takeda's Candesartan Will Be UK
29 September 1997
Irbesartan Debuts In The UK And Germany
25 September 1997
Irbesartan To Reach First Markets This Month
3 September 1997
Strong Advance In 1st-Half Profits At Novartis
29 August 1997
Novartis To Test Diovan In CHF
28 August 1997
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
